Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In spite of the improvement of conventional medical therapy for cancer treatment, the impact on cancer related mortality in the last ten years has been modest especially for advanced disease in adults. On the other hand, understanding of molecular events underlining tumor development lead to the definition of new molecular targets for novel anti-tumor therapeutical approaches. On this regard, several biotechnology products selected by academic as well as industrial research are currently in clinical trials. Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anticancer therapy. In addition, the heterogeneity of tumor cells within a selected neoplastic lesions as well as the redundancy of proliferative and survival pathways present in cancer cells favor the development of single drugs that are able to affect multiple pathways. Inhibitors of heat shock protein 90 and of histone deacetylase are two novel classes of multi-target agents that entered recently in clinical studies. This review will focus on the most important issues in the development of both these classes of agents.

Original languageEnglish
Pages (from-to)337-351
Number of pages15
JournalCurrent Drug Targets
Volume6
Issue number3
DOIs
Publication statusPublished - May 2005

Fingerprint

HSP90 Heat-Shock Proteins
Histone Deacetylases
Tumors
Cells
Pharmaceutical Preparations
Industrial research
Neoplasms
Oncology
Biotechnology
Redundancy
Post Translational Protein Processing
Epigenomics
Proteins
Clinical Trials
Mortality
Therapeutics
Research

Keywords

  • Epigenetics
  • ErbB
  • Heat shock protein 90
  • Heat shock protein 90 inhibitors
  • Histone deacetylase
  • Histone deacetylase inhibitors
  • Multi-chaperone
  • Multi-targets drugs

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Multiple-target drugs : Inhibitors of heat shock protein 90 and of histone deacetylase. / Budillon, A.; Bruzzese, F.; Di Gennaro, E.; Caraglia, M.

In: Current Drug Targets, Vol. 6, No. 3, 05.2005, p. 337-351.

Research output: Contribution to journalArticle

@article{0430b66e15ca4f24825d31e2ca7b551a,
title = "Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase",
abstract = "In spite of the improvement of conventional medical therapy for cancer treatment, the impact on cancer related mortality in the last ten years has been modest especially for advanced disease in adults. On the other hand, understanding of molecular events underlining tumor development lead to the definition of new molecular targets for novel anti-tumor therapeutical approaches. On this regard, several biotechnology products selected by academic as well as industrial research are currently in clinical trials. Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anticancer therapy. In addition, the heterogeneity of tumor cells within a selected neoplastic lesions as well as the redundancy of proliferative and survival pathways present in cancer cells favor the development of single drugs that are able to affect multiple pathways. Inhibitors of heat shock protein 90 and of histone deacetylase are two novel classes of multi-target agents that entered recently in clinical studies. This review will focus on the most important issues in the development of both these classes of agents.",
keywords = "Epigenetics, ErbB, Heat shock protein 90, Heat shock protein 90 inhibitors, Histone deacetylase, Histone deacetylase inhibitors, Multi-chaperone, Multi-targets drugs",
author = "A. Budillon and F. Bruzzese and {Di Gennaro}, E. and M. Caraglia",
year = "2005",
month = "5",
doi = "10.2174/1389450053765905",
language = "English",
volume = "6",
pages = "337--351",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Multiple-target drugs

T2 - Inhibitors of heat shock protein 90 and of histone deacetylase

AU - Budillon, A.

AU - Bruzzese, F.

AU - Di Gennaro, E.

AU - Caraglia, M.

PY - 2005/5

Y1 - 2005/5

N2 - In spite of the improvement of conventional medical therapy for cancer treatment, the impact on cancer related mortality in the last ten years has been modest especially for advanced disease in adults. On the other hand, understanding of molecular events underlining tumor development lead to the definition of new molecular targets for novel anti-tumor therapeutical approaches. On this regard, several biotechnology products selected by academic as well as industrial research are currently in clinical trials. Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anticancer therapy. In addition, the heterogeneity of tumor cells within a selected neoplastic lesions as well as the redundancy of proliferative and survival pathways present in cancer cells favor the development of single drugs that are able to affect multiple pathways. Inhibitors of heat shock protein 90 and of histone deacetylase are two novel classes of multi-target agents that entered recently in clinical studies. This review will focus on the most important issues in the development of both these classes of agents.

AB - In spite of the improvement of conventional medical therapy for cancer treatment, the impact on cancer related mortality in the last ten years has been modest especially for advanced disease in adults. On the other hand, understanding of molecular events underlining tumor development lead to the definition of new molecular targets for novel anti-tumor therapeutical approaches. On this regard, several biotechnology products selected by academic as well as industrial research are currently in clinical trials. Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anticancer therapy. In addition, the heterogeneity of tumor cells within a selected neoplastic lesions as well as the redundancy of proliferative and survival pathways present in cancer cells favor the development of single drugs that are able to affect multiple pathways. Inhibitors of heat shock protein 90 and of histone deacetylase are two novel classes of multi-target agents that entered recently in clinical studies. This review will focus on the most important issues in the development of both these classes of agents.

KW - Epigenetics

KW - ErbB

KW - Heat shock protein 90

KW - Heat shock protein 90 inhibitors

KW - Histone deacetylase

KW - Histone deacetylase inhibitors

KW - Multi-chaperone

KW - Multi-targets drugs

UR - http://www.scopus.com/inward/record.url?scp=18744396967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744396967&partnerID=8YFLogxK

U2 - 10.2174/1389450053765905

DO - 10.2174/1389450053765905

M3 - Article

C2 - 15857292

AN - SCOPUS:18744396967

VL - 6

SP - 337

EP - 351

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 3

ER -